^
    Apply
    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/02/2021
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    TP53 • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab)
    Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/10/2018
    Primary completion :
    03/15/2030
    Completion :
    03/15/2031
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL (NCT01496976)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/30/2012
    Primary completion :
    10/06/2021
    Completion :
    03/25/2025
    CD20 • CD5
    |
    lenalidomide • Arzerra (ofatumumab)
    Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/23/2021
    Primary completion :
    04/27/2027
    Completion :
    04/30/2027
    EGFR • IGH
    |
    cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2026
    Completion :
    03/31/2030
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers (NCT00788684)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    07/21/2009
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • navitoclax (ABT 263)
    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (NCT05470491)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    01/26/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2027
    IGH
    |
    bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor
    Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (NCT02160015)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2014
    Primary completion :
    03/27/2017
    Completion :
    08/13/2025
    CD20 • CD4 • CD5 • FCER2
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)
    A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia (NCT06637501)
    Phase 2
    BeiGene
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/14/2024
    Primary completion :
    10/01/2027
    Completion :
    06/01/2030
    BCL2
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL (ONO-7018-01) (NCT05515406)
    Phase 1
    Ono Pharmaceutical Co. Ltd
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/13/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    MALT1
    |
    ONO-7018
    A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (BGB-11417-108) (NCT06697184)
    Phase 1/2
    BeiGene
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/23/2025
    Primary completion :
    06/01/2027
    Completion :
    12/31/2027
    BCL2
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL (ASCEND) (NCT02970318)
    Phase 3
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/02/2017
    Primary completion :
    09/03/2021
    Completion :
    10/01/2027
    CD5 • FCER2
    |
    CD20 positive
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine
    A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (GO29781) (NCT02500407)
    Phase 1/2
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    09/15/2015
    Primary completion :
    05/21/2024
    Completion :
    09/30/2025
    CD20
    |
    Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)
    CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PRO00037171) (NCT04186520)
    Phase 1/2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/18/2020
    Primary completion :
    06/30/2026
    Completion :
    06/01/2028
    BCL2
    |
    CAR-20/19-T Cells
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    11/05/2015
    Primary completion :
    01/25/2018
    Completion :
    07/01/2025
    HLA-DRB1
    |
    Triplex (CMV-MVA vaccine)
    Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) (NCT04008706)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/17/2019
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    TP53 • CD20 • IGH • CD5 • FCER2
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (M23-647) (NCT05753501)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/09/2023
    Primary completion :
    03/01/2031
    Completion :
    03/01/2031
    ALK • BCL2 • BCL6
    |
    ALK positive
    |
    ABBV-101
    CLL Therapy Approaches in Russia (CLL registry) (NCT05140369)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/29/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    TP53 • IGH
    |
    TP53 mutation
    Vaccine Responses in Patients With B Cell Malignancies (NCT05170399)
    Phase 4
    National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    09/14/2022
    Primary completion :
    08/16/2025
    Completion :
    08/16/2025
    BCL2
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878)
    Phase 1/2
    Oncternal Therapeutics, Inc
    Completed
    Last update posted :
    02/12/2025
    Initiation :
    01/03/2018
    Primary completion :
    09/25/2024
    Completion :
    09/25/2024
    BCL2
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)
    Optimizing PTCy Dose and Timing (NCT03983850)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/09/2019
    Primary completion :
    05/31/2025
    Completion :
    05/29/2026
    KRAS • PTEN • IGH • FBXW7
    |
    KRAS mutation • RAS mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous
    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). (NCT05947851)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/08/2023
    Primary completion :
    06/27/2033
    Completion :
    06/27/2033
    TP53 • BTK • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)
    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04169737)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2026
    Completion :
    07/09/2026
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (A041702) (NCT03737981)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/31/2019
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    CD20 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (NCT03701282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/12/2019
    Primary completion :
    05/07/2028
    Completion :
    05/07/2028
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (NCT02629809)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/18/2016
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    IGH
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/07/2025
    Initiation :
    08/03/2012
    Primary completion :
    11/29/2018
    Completion :
    09/01/2020
    ER • AFP
    |
    Istodax (romidepsin)
    Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated with Pirtobrutinib After Previous Treatment with Zanubrutinib (PIPOZA) (NCT06812715)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Not yet recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/01/2025
    Primary completion :
    05/01/2029
    Completion :
    05/01/2031
    BTK
    |
    Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib)
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05672251)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/02/2024
    Primary completion :
    04/22/2025
    Completion :
    04/22/2025
    CD20
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia (NCT05672355)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/01/2023
    Primary completion :
    01/12/2026
    Completion :
    01/12/2026
    IFNG
    Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (SWOG-S0703) (NCT00658814)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/01/2008
    Primary completion :
    06/01/2013
    Completion :
    03/07/2025
    CD4
    |
    azacitidine • Mylotarg (gemtuzumab ozogamicin)
    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCI-2017-01311) (NCT03246906)
    Phase 2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/11/2017
    Primary completion :
    05/03/2025
    Completion :
    05/03/2025
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous
    Safe Accelerated Venetoclax Escalation in CLL (SAVE) (NCT04843904)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    04/14/2021
    Primary completion :
    06/02/2025
    Completion :
    06/02/2030
    BCL2
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab)
    Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/04/2025
    Initiation :
    12/16/2021
    Primary completion :
    03/29/2024
    Completion :
    06/20/2024
    TP53 • BCL2
    |
    TP53 mutation • CD20 positive
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/30/2018
    Primary completion :
    06/10/2025
    Completion :
    06/10/2026
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT04540796)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    11/20/2020
    Primary completion :
    04/04/2025
    Completion :
    05/31/2025
    BCL2
    |
    rezetamig (JNJ-8780)
    Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088)
    Phase 1
    Sumithira Vasu
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    06/30/2022
    Primary completion :
    04/30/2025
    Completion :
    07/31/2026
    CD20 • CD19 • CD22
    |
    CD20 positive
    |
    cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
    Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies (NCT05797233)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    08/28/2023
    Primary completion :
    12/30/2028
    Completion :
    12/30/2029
    BCL2 • BCL6
    |
    MET expression
    |
    cyclophosphamide • fludarabine IV
    Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCI-2016-00797) (NCT02756897)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    07/07/2016
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances (NCT05110742)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    04/22/2024
    Primary completion :
    12/30/2027
    Completion :
    12/30/2027
    CD5
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL (15-H-0016) (NCT02337829)
    Phase 2
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    01/12/2015
    Primary completion :
    06/26/2020
    Completion :
    04/01/2026
    TP53
    |
    TP53 mutation
    |
    Calquence (acalabrutinib)
    Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCI-2018-00315) (NCT03479268)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/22/2018
    Primary completion :
    06/22/2025
    Completion :
    06/22/2025
    CCND1 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)